A novel ligustrazine-based nanodelivery system protects against doxorubicin-induced cardiotoxicity by targeting the SIRT5–DUSP1 axis for mitochondrial repair
Hongshuo Shi(Shandong University of Traditional Chinese Medicine), Xing Chang(Westlake University), Guobin Liu(Shuguang Hospital), You Yang(Shuguang Hospital), Zhijiang Guo(Chinese University of Hong Kong), Fenglei Zhang(Wenzhou Medical University), Man Zheng(Shandong Provincial Hospital), Jianxiao Liang(Shandong Provincial Hospital), Yifeng Nie(National Center for Nanoscience and Technology), Wenshi Xu(Shuguang Hospital), Boxian Pang(National Center for Nanoscience and Technology)
Cited by 45
Related Papers
Emerging insights into the pathogenesis and therapeutic strategies for vascular endothelial injury-associated diseases: focus on mitochondrial dysfunction
|Angiogenesis|2024|215
Advances in pathogenesis and treatment of vascular endothelial injury-related diseases mediated by mitochondrial abnormality
|Frontiers in Pharmacology|2024|125
Ligustrazine nano-drug delivery system ameliorates doxorubicin-mediated myocardial injury via piezo-type mechanosensitive ion channel component 1-prohibitin 2-mediated mitochondrial quality surveillance
|Journal of Nanobiotechnology|2025|100
Exploring the Mechanism of Ferroptosis Induction by Sappanone A in Cancer: Insights into the Mitochondrial Dysfunction Mediated by NRF2/xCT/GPX4 Axis
|International Journal of Biological Sciences|2024|71
Worldwide Research Trends on Diabetic Foot Ulcers (2004–2020): Suggestions for Researchers
|Journal of Diabetes Research|2022|69